Avacta Group PLC (LON:AVCT) has been reiterated to Corporate in a report by finnCap today.
- Updated: September 24, 2016
finnCap has reiterated Avacta Group PLC (LON:AVCT) to Corporate in a statement released on 9/22/2016.
On 08/03/2016, Numis released a statement on Avacta Group PLC (LON:AVCT) maintained the target price at 160.00GBX that suggested an upside of 0.73%.
Having a price of 102.50GBX, Avacta Group PLC (LON:AVCT) traded -2.96% lower on the day. The last closing price is down -4.46% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. AVCT has recorded a 50-day moving average of 100.34GBX and a 200-day moving average of 103.09GBX. 33,384 shares of AVCT traded hands, up from an average trading volume of 23,513
Recent Performance Chart
Avacta Group PLC has 52 week low of 83.02GBX and a 52 week high of 142.50GBX and has a market capitalization of 0 GBX.
In addition to finnCap reporting its target price, a total of 1 firm has reported on the stock. The consensus target price is 160.00GBX with 0 firms rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 equity analysts rating the company a sell.
Brief Synopsis About Avacta Group PLC (LON:AVCT)
Avacta Group plc is the developer of Affimer bio therapeutics and research reagents. The Company's segments include Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians, and Life Sciences, which provides reagents and arrays for diagnostics, drug and biomarker discovery in biotech research and development. The Company's in-house programs include Oncology, which is engaged in developing combination therapies combining multiple immune checkpoint inhibitors by making bi- and tri-specific Affimer constructs, and Blood clotting disorders, which allows Affimer therapeutics to generate the modulate blood clot formation with the potential for anti-thrombotic, as well as wound healing therapies. It focuses on its Affimer technology, which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.